Roche reports positive data from SMA treatment trial
Roche has reported positive data from the dose finding Part I FIREFISH study of Evrysdi (risdiplam) in infants with symptomatic…
25 Feb 2021
Constant Therapeutics’ drug enters Phase II trial for Covid-19 in Israel
Israel’s Rambam Medical Health Care Campus and Ziv Medical Center researchers have begun a Phase II clinical trial of Constant Therapeutics’ lead drug candidate, TXA27, for Covid-19. A pharmaceutical formulation…
25 Feb 2021
Takeda doses first subject in Japanese Covid-19 vaccine trial
Takeda Pharmaceutical has dosed the first subject in its Phase I/II study of Novavax’s Covid-19 vaccine candidate, TAK-019, in Japan. The placebo-controlled study will assess the safety and immunogenicity of…
24 Feb 2021
Ireland’s ICON signs agreement to acquire PRA Health Sciences
Irish company ICON has agreed to acquire contract research company PRA Health Sciences in a cash and stock deal valued at about $12bn. The acquisition brings two organisations together with…
24 Feb 2021
Stealth BioTherapeutics concludes enrolment in Phase II AMD study
Stealth BioTherapeutics has completed enrolment in the Phase II ReCLAIM-2 study (SPIAM-202) of its lead product candidate, elamipretide, in patients with dry age-related macular degeneration (AMD) with geographic atrophy (GA).…
24 Feb 2021
NeuroRx’s Zyesami accelerates recovery in Covid-19 trial
NeuroRx has reported that the Phase IIb/III trial of Zyesami (aviptadil, previously RLF-100) showed multidimensional benefit in treating respiratory failure in critically ill Covid-19 patients. It was initially approved as…
23 Feb 2021
Yale announces new trial to reduce Covid-19 complications with new therapy combo
Yale School of Medicine has announced a randomised clinical trial led by the Yale Cardiovascular Research Group (YCRG) to study a therapy combination to reduce complications in Covid-19 patients. YCRG…